Literature DB >> 33217177

Increase in drugs-of-abuse findings in post-mortem toxicology due to COVID-19 restrictions-First observations in Finland.

Claudia Mariottini1, Ilkka Ojanperä1,2, Pirkko Kriikku1,2.   

Abstract

A lot has been published on the anticipated effects of the current COVID-19 pandemic on users of illegal drugs. In this study, we present evidence-based data on such effects, namely, the increased number of drug findings in post-mortem investigations. All post-mortem toxicology cases positive for at least one of the following: buprenorphine, amphetamine or cannabis, were investigated in the first 8 months of the year 2020, and the monthly numbers were compared to those in the previous 5 years from 2015 to 2019. These substances served as indicator analytes that could reveal changes in the drug using population. Right after the government restrictions came into force in March 2020, the numbers of buprenorphine, amphetamine and cannabis findings increased. The increase was most noticeable for amphetamine and was evident in all age groups. Our findings indicate that the assumptions on the increased risk of drug-related harm (including death) have become reality. Reduced access to harm-reduction services seems to have increased the mortality among individuals that use buprenorphine, amphetamine or cannabis. Significant and prompt actions need to be taken in order to find new ways in helping this vulnerable group of people.
© 2020 John Wiley & Sons, Ltd.

Entities:  

Keywords:  COVID-19; drug-related death; harm-reduction; post-mortem toxicology

Mesh:

Substances:

Year:  2020        PMID: 33217177     DOI: 10.1002/dta.2982

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  6 in total

1.  Non-COVID outcomes associated with the coronavirus disease-2019 (COVID-19) pandemic effects study (COPES): A systematic review and meta-analysis.

Authors:  Vincent Issac Lau; Sumeet Dhanoa; Harleen Cheema; Kimberley Lewis; Patrick Geeraert; David Lu; Benjamin Merrick; Aaron Vander Leek; Meghan Sebastianski; Brittany Kula; Dipayan Chaudhuri; Arnav Agarwal; Daniel J Niven; Kirsten M Fiest; Henry T Stelfox; Danny J Zuege; Oleksa G Rewa; Sean M Bagshaw
Journal:  PLoS One       Date:  2022-06-24       Impact factor: 3.752

2.  Changes in Substance Use Among People Seeking Alcohol and Other Drug Treatment During the COVID-19 Pandemic: Evaluating Mental Health Outcomes and Resilience.

Authors:  Molly Carlyle; Janni Leung; Zoe C Walter; Jennifer Juckel; Caroline Salom; Catherine A Quinn; Lily Davidson; Rhiannon Ellem; Grace Newland; Leanne Hides
Journal:  Subst Abuse       Date:  2021-12-06

3.  Temporal monitoring of stimulants during the COVID-19 pandemic in Belgium through the analysis of influent wastewater.

Authors:  Tim Boogaerts; Maarten Quireyns; Maarten De Prins; Bram Pussig; Hans De Loof; Catharina Matheï; Bert Aertgeerts; Virginie Van Coppenolle; Erik Fransen; Adrian Covaci; Alexander L N van Nuijs
Journal:  Int J Drug Policy       Date:  2022-04-04

4.  HIV Care Continuum Services for People Who Inject Drugs in Kazakhstan During COVID-19: A Qualitative Study of Service Provider Perspectives.

Authors:  Tara McCrimmon; Anne Sundelson; Meruyert Darisheva; Louisa Gilbert; Timothy Hunt; Assel Terlikbayeva; Sholpan Primbetova; Nabila El-Bassel
Journal:  Glob Health Sci Pract       Date:  2022-04-29

Review 5.  Have Deaths of Despair Risen during the COVID-19 Pandemic? A Systematic Review.

Authors:  Hania Rahimi-Ardabili; Xiaoqi Feng; Phi-Yen Nguyen; Thomas Astell-Burt
Journal:  Int J Environ Res Public Health       Date:  2022-10-07       Impact factor: 4.614

Review 6.  Opioids in COVID-19: Two Sides of a Coin.

Authors:  Camila Vantini Capasso Palamim; Matheus Negri Boschiero; Aléthea Guimarães Faria; Felipe Eduardo Valencise; Fernando Augusto Lima Marson
Journal:  Front Pharmacol       Date:  2022-01-06       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.